New cell therapy takes aim at Hard-to-Treat cancers

NCT ID NCT06478251

Recruiting now Disease control Sponsor: TingBo Liang Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 05, 2026 · Updated 15 times

Summary

This early-phase study tests a new cell therapy (NW-301V or NW-301D) in 9 adults with advanced solid tumors that have specific KRAS mutations (G12V or G12D) and no standard treatment options. Participants receive their own immune cells that have been genetically engineered to recognize and attack cancer cells. The main goal is to check safety and find the right dose, while also looking at whether the tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Zhejiang University school of Medicine
RECRUITING

Hangzhou, Zhejiang, China

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

TUMOR, SOLID